The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study
Abstract
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306
Powers, J. H., Patrick, D. L., Walton, M. K., Marquis, P., Cano, S., Hobart, J., Isaac, M., Vamvakas, S., Slagle, A., Molsen, E., et al. (2017) · Value in Health · doi:10.1016/j.jval.2016.11.005 · Cited by 191
Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers
Lodise, T. P., Drusano, G. L., Butterfield, J. M., Scoville, J., Gotfried, M., & Rodvold, K. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-11 · Cited by 60
Metadata
- Authors
- Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-01
- Volume
- 32
- Issue
- 3
- Pages
- 402-412
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2128076923
- Cited by
- 440
- References
- 1
- FWCI
- 30.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study. https://app.cochat.ai/papers/10.1086/318486
- The paper
- Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group. (2001). Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study. Clinical Infectious Diseases. https://doi.org/10.1086/318486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
